Autor: |
Bougnoux, Ph., Delva, R., Serin, D., Namer, M., Piot, G., Lotz, J.P., Ramée, J.F., Vuillemin, E., Grau, B., Roubinet, A., Soares, J.A., Chazard, M. |
Zdroj: |
European Journal of Cancer; November 1995, Vol. 31 Issue: 6 pS82-S82, 1p |
Abstrakt: |
We report the preliminary results on 50 out of 86 pts enrolled to an ongoing trial of Taxol (T) as 2nd line treatment for MBC. T dose is 225mg/m2(3-h infusion) q3w without G-CSF. Eligibility criteria: age 18–75. ECOG PS ≤2, measurable disease and adequate organ function. Pts characteristics are: median (med) age 55 (range 36–76); med ECOG PS 1 (0–2); 24 pts received prior adjuvant + metastatic CT (group A) and 26 pts received only 1 prior metastatic CT (group B). Patients received a total of 217 cycles with a med number of T courses/pt of 4 (1–11). Fourty-nine pts are evaluable for toxicity and 46 for efficacy.Grade III/IV neutropenia was observed in 58% cycles. Febrile neutropenia was reported in only 3% cycles and grade III anemia in 5% cycles. No thrombocytopenia grade ≥3 was reported. Peripheral neuropathy grade ≥2 was noted in 31 pts: 20 (41%) grade II and 11 (22%) grade III. The med cumulative dose of T at appearance of grade III neuropathy was 900mg/m2(450–1350). There were 2 CR, 11 PR, 22 SD and 11 PD, for an objective response rate of 28% (group A: 15%; group B: 38%). |
Databáze: |
Supplemental Index |
Externí odkaz: |
|